The First Big C Pharmaceutical? Why Hengrui’s $15.2B BMS Alliance Matters

A global drug development thought exercise about a Chinese pharma operating with the clinical ambition and global integration of a Tier-1 multinational

May 14th, 2026 May 30th, 2028

Citrini Research’s thought exercise on Substack, “The 2028 Global Intelligence Crisis”, has been described as one of the most provocative scenario analyses of 2026: a hypothetical June 2028 memo that mapped how AI could generate “Ghost GDP,” hollow out white‑collar work, and destabilize financial markets while headline productivity surged. That piece invited investors to think in scenarios, not straight‑line forecasts.

Announced on May 12, 2026, Hengrui’s alliance with Bristol Myers Squibb (BMS) is a fabulous opportunity to apply that style of thinking to global drug development value chains, despite this article being written with far fewer resources (myself, so any errors and omissions are mine alone).

Two years on, we might look back at this deal not just as a transaction, but as a lens on how global drug development and capital were already re‑wiring themselves. What follows is a thought exercise in global drug development, hypothetically written on May 30, 2028, about a deal signed in May 2026.

The Moment We Didn’t Fully Understand: May 2026

In 2026, the BMS-Hengrui announcement landed: Up to $15.2 billion, with $600 million upfront, $175 million payments in years 2 and 3, symmetrical territorial rights, and 13 early-stage assets. BMS’ inclusion of four of its immunology assets in China, Hong Kong, and Macau in the deal was the eyebrow-raiser. In 2025, GSK paid $500 million upfront to license one Hengrui candidate and secure options on 11 other programs. This GSK deal, which is worth up to $12 billion, positioned Hengrui to advance the assets through phase 1.

What we didn’t realize then, the BMS-Hengrui alliance wasn’t primarily a financing deal. It was the first all-in step into global innovation platform integration. BMS wasn’t just buying optionality on Hengrui’s oncology pipeline. They were buying something more valuable: access to one of China’s best high-velocity clinical development engines that big pharma needed to win first-mover advantage and global market share.

And Hengrui wasn’t just monetizing assets. They were acquiring the organizational muscle memory of a global pharmaceutical’s clinical trial infrastructure, regulatory playbooks, and commercialization, marketing, as well as distribution know-how for the rest of the world. That exchange—that was the real deal.

This deal was one of the earliest signs that Hengrui was on track to become something much larger by 2028: the first of the “Big C Pharmaceuticals,” a Chinese pharmaceutical company operating with the breadth, clinical ambition, and global integration of a Tier-1 multinational. The $950 million received from BMS from 2026 to 2028 functioned as non‑dilutive capital that allowed Hengrui to sustain approximately 27–28% R&D intensity without tapping equity markets.

What the Retrospective View Shows: The Velocity Arbitrage

Here’s what we can see from 2028 that wasn’t visible in mid-2026: the BMS-Hengrui partnership was structured to solve a very specific problem that was only going to get worse.

What Hengrui and BMS essentially did was create a velocity arbitrage. Hengrui could burn capital at rates that could bankrupt a comparable international competitor, because they had (a) access to non-dilutive capital, (b) a trial infrastructure that could run multiple programs in parallel at a cost-per-patient that Western pharmaceuticals couldn’t match, and (c) a regulatory pathway in China that had become, by 2026, genuinely competitive with the FDA for speed-to-first-in-human.

By 2028, that arbitrage has become the template for how Big Pharma thinks about external innovation. It's not about accessing pipeline assets anymore. It's about accessing execution capabilities from partners who can move faster and cheaper than you can internally.

And that realization created an uncomfortable geopolitical tension in Washington.

Throughout 2026, U.S. lawmakers increasingly discussed restricting the use of China-generated clinical data and reducing dependence on Chinese clinical trial infrastructure.

As of 2028, these proposals have never made it into legislation as lawmakers realized clinical development is a globally competitive market for time, patients, and execution. Attempts to suppress Chinese clinical velocity without materially improving the speed and efficiency of U.S. trials amount to leveling down rather than leveling up. European pharmaceutical companies (say BMS, GSK, Merck) would double down on their China partnerships to the detriment of U.S. Big Pharma’s clinical development pipelines.

The Assets That Mattered

What mattered was that Hengrui had demonstrated, through their 2025–2026 approval cadence, that they could run a discovery-to-IND pipeline that generated multiple developable assets per year. Seven Class 1 innovative drug approvals in 2025 alone. The BMS deal essentially said: “We’re going to bet on your process, not your individual molecules.”

By 2028, of the 13 original programs in the BMS-Hengrui collaboration, four have advanced to IND-equivalent status globally. Two are in formal Phase 1b trials in China, with corresponding registrational pathways being planned for ex-China territories. The others remain in preclinical development or very early IND-enabling studies. That’s exactly the attrition rate you’d expect from a program that was early-stage in 2026.

The joint discovery programs—the five co-developed assets from scratch—have become the real engine of the collaboration. They forced both organizations to operationalize a genuinely integrated development model. Trial sites in China. Regulatory submissions coordinated across NMPA, EMA, and FDA in parallel. Real-time data sharing. Hengrui contributing clinical expertise in Chinese patient populations; BMS contributing global regulatory and manufacturing infrastructure.

Two of the four original Hengrui-originated oncology programs in the BMS collaboration advanced far enough by late 2027 that they required serious global development and commercialization planning. BMS took the lead on global regulatory strategy and pre-commercial planning for ex-China markets. But Hengrui didn’t step into a passive vendor role. Instead, they built out an international clinical operations team, hired regulatory affairs expertise for EU and US markets, and started bidding on parts of the global development work.

By mid-2028, Hengrui is co-running these programs in a way that looks much more like two equal partners than a licensing relationship. They’re not just collecting royalties on BMS’ sales.

Being able to execute as a genuine global biotech is now transferable to Hengrui’s non-BMS programs. They’re using the same regulatory expertise, the same clinical trial infrastructure, the same pre-commercial machinery on programs from their standalone pipeline.

The globalization strategy that looked aspirational and the R&D spend that looked too aggressive for a Chinese pharmaceutical leader in 2026? It’s now operationalized and just right, respectively.

About the author

JX (Jaxon) Tan founded Momentum AI Communications, a boutique PR consultancy based in Singapore, with a mission to simplify science and spark engagement. He was previously based in China, where he led international communications for BGI Genomics and was head of content (APAC) for PR Newswire. Reach him on LinkedIn.